Drugs / levalbuterol tartrate HFA inhalation aerosol
levalbuterol tartrate HFA inhalation aerosol
also known as
Xopenex HFA (Levalbuterol tartrate) Inhalation Aerosol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02150499 | Jul → Dec 2014 | asthma | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levalbuterol tartrate HFA inhalation aerosol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02150499 ↗ |
| Known as | Xopenex HFA (Levalbuterol tartrate) Inhalation Aerosol | “Xopenex HFA® (Levalbuterol tartrate) Inhalation Aerosol” NCT02150499 ↗ |
| Route | Inhaled | “levalbuterol tartrate HFA inhalation aerosol MDI using a valved holding chamber and facemask” NCT02150499 ↗ |